Searching for a binding protein in blood, which may be involved in the specific transport of cardiac glycosides to their receptor sites on the sodium pump, we isolated a cardiac glycoside-binding protein ( 
ϩ -ATPase (EC 3.6.1.37), the biochemical equivalent of the sodium pump of mammalian cell membranes. They inhibit in vivo in the nanomolar concentration range (1) . The cardiac glycoside sensitivity varies with the isoenzyme form of Na ϩ /K ϩ -ATPase. Since the tissue distribution of these isoenzyme forms varies (2) , cardiac glycosides may inhibit the sodium pump in various tissues with different efficiency.
Szent Gyorgyi suggested in 1953 (3) that cardiac glycosides are not drugs, but a substitute for an endogenous compound that is a physiological regulator of heart muscle contraction. Consistent with this hypothesis, a number of cardiotonic steroids have recently been isolated from various mammalian tissues and fluids (4, 5) . Among those are the cardenolides ouabain or its isomer (6 -9) , digoxin (10) , and the bufadienolides 19-norbufalin (11) and marinobufagenin (12, 13) . Additional, yet unknown, substances seem to exist (14) . Ouabain or its isomer has been shown to be secreted from bovine cortical adrenal cells of the zona glomerulosa in tissue culture (15, 16) stimulated with angiotensin II (17) . Prolonged administration of low concentrations of ouabain raises blood pressure in rats (18) . Low concentrations of ouabain increase the expression of early and late response genes in heart cells (19, 20) . Moreover, Gottlieb et al. (21) reported that the level of the endogenous ouabain-like substance increases in patients with congestive heart failure. All these data are consistent with the idea that the endogenous ouabain may represent a new type of a steroid hormone of mammals (22) .
Steroid hormones are normally transported in blood bound to specific globulins (23) . Provided endogenous ouabain represents in fact a new type of a steroid hormone, then it should be expected that a specific globulin with high affinity for cardiac glycosides exists. The present knowledge is that cardiac glycosides are bound in blood to serum albumin (24) . The apparent dissociation constants of the serum albumin-cardiac glycoside complexes is in the millimolar concentration range, which is about 10 6 times above the therapeutic cardiac glycoside concentration (1). Lichtstein et al. (25) showed recently that digitalis-like compounds are normal constituents of toad blood and that 30% thereof are bound to plasma proteins of M r ϭ 48 -53 ϫ 10
3 . This finding encouraged us to investigate the possibility that mammals may have a specific cardiotonic steroid-binding globulin (CGBG) 1 in their blood plasma, and the present paper reports evidence in support of this. A preliminary report has been given (26) .
EXPERIMENTAL PROCEDURES
Chemicals of the highest available purity were from Boehringer Mannheim (Mannheim, Germany), Merck (Darmstadt, Germany), Serva (Heidelberg, Germany), Sigma-Aldrich (Steinheim, Germany) and colloidal Coomassie blue from ICN (Costa Mesa, CA). Digoxigenin antibodies, the digoxigenin detection kit, and the "digoxigenin-glycan differentiation kit" were purchased from Boehringer Mannheim. Resource-S and CNBr-activated Sepharose were obtained from Amersham Pharmacia Biotech (Freiburg, Germany), and protein A-Sepharose was from Zymed (San Francisco, CA). The Red-A-agarose and the ultrafiltration system were from Amicon. Molecular weight markers were from Amersham Pharmacia Biotech and Bio-Rad. Incomplete Freund's adjuvant was from Sigma. Schleicher & Schü ll supplied nitrocellulose BA 85 and Millipore polyvinylidene fluoride membrane Immobilon-P.
Preparation of CGBG Antisera
Impure fractions of CGBG were essentially prepared as described earlier (26) . Briefly, the bovine serum globulin fraction was given at pH 8.0 to a CM-Sephadex C50 column. The CGBG eluting at pH 9.1-10.5 was applied in fractions of 15 mg per run to a 1-ml Resource-S column in a fast performance liquid chromatography system. A linear gradient from 0 to 0.5 M NaCl in sodium acetate buffer, pH 5.5, with a velocity of 4 ml/min was applied. CGBG eluted at 0.4 M NaCl. The protein was dialyzed against 20 mM potassium phosphate buffer, pH 7.0, and then subjected to dye-ligand chromatography on a Red-A column (1.7 ϫ 8.0 cm). Impurities were removed by applying a salt gradient from 0 to 1.5 M KCl in 20 mM KH 2 PO 4 at pH 7.0. CGBG eluted at a concentration of 125 mM KCl. Heavy chains of IgG as contaminants were separated by a protein A-Sepharose affinity column (1.5 ϫ 2.0 cm) (27) . To remove any additional impurities, CGBG was subjected to SDS-PAGE in 10% slab gels (28) and the protein band at M r ϭ 67 ϫ 10 3 (K-60 antibody) was cut out from the gel and dialyzed against water at 4°C for 2 days. The gel pieces were then homogenized in 0.9% NaCl in a Potter-Elvehjem homogenizer. The rabbits were immunized intracutaneously with 500 l of gel homogenate. The protein (100 g) was then thoroughly mixed with an equal volume of complete Freund's adjuvant. Small portions of the antigen were injected intracutaneously along the vertebrae of the rabbits. The animals were boostered after 4 weeks with approximately the same amount of the protein and additional booster injections followed in irregular time intervals. One week after the last injection, up to 20 ml of blood was taken from the ear vein. The complement in the serum was inactivated by heating for 15 min at 56°C. The IgG fraction of the serum was then isolated from the globulin fraction by affinity chromatography on protein A-Sepharose (27) . IgG eluting with 0.1 M citric acid, pH 3.0, from the column was neutralized immediately with Tris base and subsequently dialyzed against 50 mM Tris/HCl, pH 7.5, containing 150 mM NaCl (TBS). It was stored at Ϫ80°C.
Antibodies against the 30-kDa band (K-30 antibody) were raised by a similar procedure. Purified CGBG was boiled first with 10% ␤-mercaptoethanol (0.35 M) for 5 min in a water bath and subjected then to a preparative 8% SDS-gel electrophoresis in a Bio-Rad Prep-Cell machine (Richmond, VA). From the 4.5-cm-high 8% SDS gel at a constant electric power of 12 watts, the 30-kDa protein eluted in 8 h.
Immunological and Analytical Assays
The specificity of the antibodies against the cardiac glycoside-binding globulin was tested in dot blots of chromatograms of the CGBG purification procedures as well as in Western blots after the SDS-PAGE. Proteins were detected by Coomassie colloidal Blue (ICN). To ascertain the specificity of the antibody, HDMA affinity labeling of the protein fraction of interest was performed in parallel (Ϯ10 Ϫ4 M ouabain). In short, dot blots of fractions were tested after neutralization of the fractions eluting from the respective columns. When Western blots were performed, gels and nitrocellulose membranes were soaked for 20 min in blot buffer (10 mM CAPS, 20% methanol, pH 11). Electrophoretic protein transfer to the nitrocellulose membrane BA 85 sheets was in a CTI blot apparatus at 5 mA/cm 2 /15 min. The transfer of proteins was verified by reversible Ponceau staining (0.2% Ponceau dye (w/v) in 1% acetic acid). The membranes were then destained by shaking in TBS buffer, pH 7.5, and free binding sites of the nitrocellulose membrane were blocked with 1% Boehringer Mannheim blocking solution. This step was followed by incubation with anti-CGBG IgG diluted 1:1000 in 0.5% blocking solution. Unreacted IgGs were removed by washing the membranes four times for 15 min at room temperature in TBS/HCl, pH 7.5, 0.1% Tween 20. The protein-IgG complexes formed were detected with anti-rabbit IgG linked to horseradish peroxidase (27) . The peroxidase reaction proceeded at room temperature using 0.3 mg of 3,3Ј-diaminobenzidine tetrahydrochloride dihydrate/ml of TBS, pH 7.5, and 0.01% H 2 O 2 as substrate solution.
Purification of a Cardiac Glycoside-binding Protein from Bovine Blood
Preparation of the Globulin Fraction-If not otherwise mentioned all steps were performed at 4°C. Bovine blood (10 liter) was obtained from a local slaughterhouse. After clotting at room temperature and retraction at 4°C, serum was obtained by centrifugation at 5000 ϫ g for 20 min. The globulin fraction was obtained by ammonium sulfate precipitation (50%) and centrifugation at 5500 ϫ g for 15 min. The sediment was dissolved in 100 mM glycine buffer, pH 8.0, containing 150 mM NaCl and dialyzed at 5°C in the same buffer for 12 h. Protein concentration was determined according to Lowry et al. (29) or according to Warburg and Christian (30) .
Cation Exchange Chromatography on CM-Sephadex C50 -The globulin fraction (ϳ8 -10 g of total protein) was loaded onto a CM-Sephadex C50 column (5.5 ϫ 50 cm) that had been equilibrated in 100 mM glycine/NaOH, 150 mM NaCl buffer, pH 8.0. The column was washed extensively with the same buffer until the absorbance at 280 nm reached the starting equilibration value. Bound proteins were then eluted with 850 ml of the glycine/NaOH buffer containing 150 mM NaCl with a pH gradient from 8.0 to 10.0. Fractions containing cardiac glycoside-binding protein were eluted at pH 9.1-10.5. They were concentrated by pressure dialysis at 0°C.
Affinity Chromatography of the Cardiac Glycoside-binding Globulin on an Antibody Column-Rabbit IgG against the cardiac glycosidebinding protein (K-60 antibody) was coupled to CNBr-activated Sepharose 4B at pH 8.0. The eluate fractions of the CM-Sephadex cation exchange chromatography interacting specifically with HDMA (31) were given to a 25-ml antibody column that had been equilibrated with 0.1 M glycine/NaOH buffer, pH 8.0, containing 0.5 M NaCl and 0.04% NaN 3 . The column was washed until the absorbance at 280 nm of the eluate reached the base line of the equilibration buffer (ϳ100 ml). The cardiac glycoside-binding protein was then eluted from the column with 0.1 M sodium acetate, pH 4.5, containing 0.5 M NaCl. The fractions containing CGBG were immediately neutralized by 1 M Tris/HCl buffer, pH 7.2, and additionally concentrated by ultrafiltration.
Affinity Chromatography of the Cardiac Glycoside-binding Globulin on Ouabain-Sepharose 4B-Several ml of the former step were given to a ouabain-Sepharose column (1 ml) that had been equilibrated with 100 mM Tris/HCl, pH 7.5, containing 150 mM NaCl. After washing with the same buffer for several minutes 100 mM sodium acetate, pH 4.5, containing 0.5 M NaCl was added. The column was perfused in a high performance liquid chromatography device with a velocity of 1 ml/min.
Affinity Labeling of the Cardiac Glycoside-binding
Globulin by HDMA Cardiac glycoside-binding globulin (0.5 mg/ml) was incubated for 1 h at 37°C with 1.0 -5.0 ϫ 10 Ϫ9 M HDMA in TBS/HCl buffer, pH 7.2, in the presence or absence of 0.1 mM ouabain or other steroids. After 10% SDS-PAGE, transfer to nitrocellulose membranes, and consecutive treatment with polyclonal anti-digoxigenin antibodies conjugated to horseradish peroxidase, HDMA-labeled proteins were detected by use of chemiluminescence (digoxigenin detection kit of Boehringer Mannheim and Kodak films).
The excitation wavelength was set at 284 nm with a slit width of 3 nm. The emission wavelength was set at 335 nm with a slit width of 5 nm. Cardiac glycoside-binding globulin (0.3-0.6 mg) was diluted in 1.5 ml of 0.1 M TBS/HCl buffer, pH 7.2, at room temperature in a cuvette containing a stirring bar. Ouabain was added in increasing concentrations and the change in fluorescence intensity was recorded.
Amino Acid Sequence Analysis of the N Terminus of the "Cardiac Glycoside-binding Globulin"
The HDMA-labeled protein was transferred to a polyvinylidene fluoride membrane and subjected to Edman degradation by pulsed liquidphase sequencing in an Applied Biosystems 477 sequencer.
RESULTS
Antibodies against a Cardiac Glycoside-binding Protein-In preliminary experiments, we were able to demonstrate the existence of a minor protein in the globulin fraction of bovine serum that was labeled specifically by the protein-reactive digoxigenin derivative HDMA (26) (Fig. 1) . Unfortunately, only impure preparations of the cardiac glycoside-binding globulin were obtained by this procedure. CGBG in the plasma globulin fraction adsorbed to the anion exchanger CM-Sephadex at pH 8.0, wherefrom it eluted at pH 9 -10. This step was followed by cation exchange chromato-graphy at pH 5.5 on Resource-S material using an NaCl gradient. Finally, dye-ligand chromatography on a Red A column (with a KCl gradient in phosphate FIG. 2 . Affinity purification of the cardiac glycoside-binding protein from bovine serum by an antibody column. The eluate of a CM-Sephadex column obtained by a pH change was applied to a (1.7 ϫ 12 cm) K-60 antibody column (22 ml) that had been equilibrated with 0.1 M glycine/NaOH buffer, pH 8.0, containing 0.5 M NaCl (buffer A). After a wash with 100 ml of the same buffer, bound cardiac glycosidebinding globulin was eluted by a linear gradient to 0.1 M sodium acetate, pH 4.5, containing 0.5 M NaCl (buffer B) at a flow rate of 1 ml/min. The protein fractions with a retention time of 10 -13 min were neutralized by 1 M Tris/HCl, pH 7.2, pooled, concentrated, and subjected to the HDMA labeling procedure and SDS-electrophoresis. They contained the protein CGBG (Fig. 4) . To an ouabain-Sepharose 4B column (1 ml) attached to a fast performance liquid chromatography instrument and equilibrated with 100 mM Tris/HCl, pH 7.5, containing 100 mM NaCl, several ml of CGBG (as 1-ml injections) were applied. After a basal value of absorbance at 280 nm was reached, a buffer change (at 5 min) to 100 mM sodium acetate, pH 4.5, containing 0.5 M NaCl eluted CGBG as a single peak (at 6.0 min). buffer, pH 7) and removal of contaminants of IgG on a protein A column gave a protein fraction that showed a major band of 67 kDa in SDS-PAGE that was labeled specifically by 5 nM HDMA, since 0.1 mM ouabain hindered the covalent modification of this protein (Fig. 1A) . When the protein of 67 kDa was excised from the SDS gel and used to immunize rabbits, a specific antibody (K-60 antibody) was obtained that did not detect other proteins in a similar semipurified preparation of the cardiac glycoside-binding protein (Fig. 1B) .
Affinity Purification of the Cardiac Glycoside-binding Protein from Bovine Serum-To facilitate purification of the cardiac glycoside-binding protein by a faster and more specific procedure, the K-60 antibody was coupled to CNBr-activated Sepharose 4B and used as a matrix for affinity chromatography. The protein fraction eluting from the CM-Sephadex column at pH 9, and containing CGBG according to affinity labeling assays with HDMA, was immediately applied to a K-60 Sepharose column. Most of the proteins passed through this column by washing with 0.1 M glycine/NaOH, pH 8.0, containing 0.5 M NaCl. Cardiac glycoside-binding protein was eluted by a change of pH to 4.5 as a single peak (Fig. 2) . Additional impurities and inactivated CGBG could be separated by affinity chromatography on ouabain-Sepharose 4B (Fig. 3) . This procedure resulted in the isolation of about 0.5 g of pure protein out of 230 mg of serum protein (1.6 liters) within 3 days. Thus, CGBG was purified 5000 times from bovine serum.
When pure cardiac glycoside-binding protein was affinitylabeled with the protein-reactive HDMA and subjected to SDS-PAGE, a single protein band of 53.2 kDa was seen by colloidal Coomassie Blue protein staining as well as by immunological digoxigenin detection (Fig. 4) . However, when the same protein was boiled with 10% ␤-mercaptoethanol prior to SDS-PAGE, a single band of 26.6 kDa was seen with both detection systems (Fig. 4) . We also raised an antibody in rabbits against the 26.6-kDa protein. This antibody (K-30 antibody) detected the protein band of 26.6 kDa in a Western blot, and the 53.2-kDa band under conditions that excluded ␤-mercaptoethanol during the boiling procedure prior to SDS-PAGE (not shown). Evidently, both proteins contain the same epitopes recognized by K-60 and K-30 antibodies. It is therefore feasible that CGBG is a homodimer of two subunits linked to each other by disulfide bonds. Evidently, cleavage of these disulfide bonds requires a reducing agent with high redox potential and hence a high concentration of ␤-mercaptoethanol. Fig. 4 of 26.6 and 53.2 kDa were excised from polyvinylidene fluoride membranes and analyzed for their N-terminal amino acid sequence by Edman degradation. They both showed the sequence K-D-V-Y-R-A-P-D-G-T-Q-S-A. No significant homology to this sequence was found by comparison with sequences of other recorded proteins in nonredundant GenBank CDS translations ϩ PDB ϩ SwissProt ϩ SPupdate PIR 207. Contrary to this homogeneity, a heterogeneity in isoelectric points (IEP or pI) of the isolated protein was found in an HDMA-labeled CGBG preparation. The majority of the protein had an IEP or pI of 4.4, but additional CGBGs with IEPs up to 5.5 were seen (not shown). To learn whether glycosylation of the CGBG might be a reason for this heterogeneity, we studied its interactions with lectins; it became evident that the cardiac glycoside-binding protein is glycosylated (Fig. 5) . The 53-kDa proteins reacted with the lectin of Sambucus nigra (elderberry bark) that interacts with terminal sialic acids bound to ␣(2-6)-galactose, with the lectin of Galanthus nivalis (snowdrop) that interacts with mannose that is terminally bound to ␣(1-3), ␣(1-6), or ␣(1-2) and with the lectin of Datura stramonium that interacts with Gal␤(1-4)GlcNAc in complex and hybrid N-glycans and O-glycans.
Chemical and Physical Properties of the Cardiac Glycosidebinding Protein-HDMA-labeled proteins in
Cardiac Glycoside-binding Properties of the Binding Protein-Affinity labeling is an efficient and specific means not only to isolate the binding protein but also to get information on the affinity and specificity of the protein for cardiac glycosides. Affinity labeling of CGBG by 5 or 100 nM HDMA could be suppressed by 10 Ϫ4 M bufadienolide proscillaridin A, the cardenolides ouabain and digoxin, but not by the steroid hormones estrogen, testosterone, progesterone, and cortisone (not shown).
To get more detailed information on the affinity of the cardiac glycosides for the cardiac glycoside-binding protein, the effect of ouabain binding on the intrinsic fluorescence of tryptophan was studied. Ouabain binding led to quenching of the tryptophan fluorescence. When the extent of quenching was studied as a function of ouabain concentration, a saturation curve was obtained (Fig. 6 ). This saturation curve could be used to quantitate the number of binding sites of the binding globulin under the conditions of the assay as 40 nM. From this capacity of sites, the ratio of free and bound ouabain could be calculated and a Scatchard plot could be constructed (Fig. 6,  inset) . As seen from this titration experiment, high and low affinity ouabain binding sites exist. Since the capacities of high and low affinity ouabain sites were almost identical in several binding experiments, we anticipated coexisting binding sites and analyzed cardiotonic steroid binding (O) to the protein (P) accordingly (Equation 1),
with an Adair-Pauling simple sequential model (32) . The following parameters were obtained for ouabain:
, and the interaction factor was 50 (Hill coefficient: 0.7).
DISCUSSION
Heart therapy with cardiac glycosides may create problems. On digitalis treatment, some patients show intoxication at concentrations that are within the therapeutic range, while other patients show no intoxication at all, even though, according to immunological criteria, their serum concentrations are in the toxic range (33) . Analysis of blood proteins has not as yet revealed any reason for this clinical observation. It is generally accepted that hydrophobic cardiac glycosides are transported in blood as their serum albumin complexes (24) . However, the hydrophilic cardiac glycoside ouabain is generally believed to circulate in blood in its free form. The present work suggests an alternative explanation: ouabain and cardiac glycosides bind to a specific plasma binding protein like other steroid hormones (23, 34 -38) that regulate gene expression via intracellular receptors (39, 40) . Yet, the cardiac glycoside-binding protein is not one of the known steroid-binding proteins such as corticosteroid or sex hormone-binding proteins, as the N-terminal amino acid analysis of CGBG and its comparison with data banks reveals. This hitherto unknown glycoprotein contained terminal sialyl residues bound to ␣(2-6)-connected galactose, terminally bound mannose, and Gal␤(1-4)GlcNAc (Fig. 5) . This results in a heterogeneity of the isoelectric points of the pure protein between 4 and 5.5, apparently due to varying glycosylation. The protein circulates as a minor protein in nanomolar concentrations in bovine serum, provided losses during the purification procedure are negligible.
The smallest protein that still binds cardiac glycosides is a 26.6-kDa protein (Fig. 4) . Since this protein is formed from a 53.2-kDa protein by heating with ␤-mercaptoethanol (Fig. 4) , the cardiac glycoside-binding protein must be a homodimer of 26.6-kDa subunits. Consistent therewith, both proteins reacted with antibodies raised against the 26.6-and 53.2-kDa proteins (Fig. 4) . Moreover, Edman degradation of the monomeric 26.6- kDa and the dimeric 53.2-kDa proteins gave the same amino acid sequence of K-D-V-Y-R-A-P-D-G-T-Q-S-A. This sequence, which is not found in the protein data banks mentioned above, excludes the possibility that the newly isolated binding globulin for cardiac glycosides is identical with serum albumin or any other known steroid-binding protein.
Also consistent with the assumption of a dimeric structure of the protein, two interacting cardiac glycoside binding sites have been detected in the isolated protein (Fig. 6) . The negative cooperativity in binding of the cardenolide ouabain indicates that we are observing a specific phenomenon of the binding globulin (Fig. 6 ). All cardiotonic steroids tested so far bind with a high affinity to this protein (not shown). The dissociation constant of 1.5 nM ouabain for the high affinity binding site is in the range of the serum concentrations of endogenous ouabain (4, 5, 15, 21, 22) , and it is also in the range found under therapeutic conditions for digoxin (33) . The negative cooperativity of cardiac glycoside binding to the CGBG is astonishing, however. This binding behavior of the CGBG means that binding of an additional cardiotonic steroid molecule is hindered when the protein already has one cardiac glycoside bound. Since the K d value of the high affinity site of CGBG is in the range of the very high affinity site of the ␣2 and ␣3 Na ϩ /K ϩ -ATPase isoforms for cardiac glycosides (41) (42) (43) , and the lower K d value of CGBG is in the range of the ␣1 Na ϩ /K ϩ -ATPase isoform, which has a low affinity for cardiac glycosides, one should ask whether CGBG may protect these isoforms from being inhibited by cardiac glycosides. We may also not exclude the possibility that a docking protein exists in specific tissues, which, upon interaction with CGBG, alters its binding properties and thereby releases transported cardiotonic steroids to the cardiac glycoside receptor of the sodium pump. For the sex steroid-binding protein, transport of steroids to the target cells through the participation of a membrane receptor is likely (for a recent review, see Ref. 44) .
The demonstration of an unknown binding protein for cardiac glycosides is consistent with the postulate that endogenous cardiac glycosides represent a new group of steroid hormones (22) and that ouabain or its isomer is a representative thereof (6 -9). The negative cooperativity of cardiotonic steroid binding is not unusual for this steroid-binding globulin. For instance, transthyretin, which is a tetramer of monomers of 55 kDa, has two thyroxin binding sites that interact in a negatively cooperative way (45) . The sex steroid-binding protein is a homodimer containing three polysaccharide chains and two disulfide bonds (46) .
